Trials / Completed
CompletedNCT01540539
Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to study the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of REGN1154 in normal healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN1154 or placebo | Participants will receive active drug or placebo |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2012-02-28
- Last updated
- 2014-01-24
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT01540539. Inclusion in this directory is not an endorsement.